Guideline-Directed Medical Therapy for Heart Failure in Muscular Dystrophy
Patients with muscular dystrophy and heart failure should receive the same guideline-directed medical therapy (GDMT) as other heart failure patients with reduced ejection fraction (HFrEF), including ACE inhibitors/ARNi, beta-blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 inhibitors, with standard ICD indications applying when meaningful survival >1 year is expected 1.
Core Treatment Algorithm
Step 1: Initiate Quadruple Therapy (Simultaneously or Sequentially)
The 2022 AHA/ACC/HFSA guidelines establish that all HFrEF patients—including those with muscular dystrophy—should receive four foundational medication classes 2:
- ACE inhibitor or ARNi (angiotensin receptor-neprilysin inhibitor)
- Beta-blocker
- Mineralocorticoid receptor antagonist (spironolactone or eplerenone)
- SGLT2 inhibitor (dapagliflozin or empagliflozin)
Start at low doses and uptitrate to target doses shown effective in clinical trials. You do not need to achieve target dosing of one medication before starting the next 2.
Step 2: Add Diuretics for Volume Overload
Use loop diuretics when pulmonary congestion or peripheral edema is present. Always combine with ACE inhibitors 3. Diuretics provide rapid symptomatic relief but should not be used as monotherapy 3.
Step 3: Consider Additional Agents Based on Race and Tolerance
For African American patients with persistent symptoms despite quadruple therapy, add hydralazine-isosorbide dinitrate 2. For patients intolerant to ACE inhibitors/ARBs due to hypotension or renal insufficiency, hydralazine-isosorbide dinitrate may be considered, though referral to a heart failure specialist is recommended 2.
Muscular Dystrophy-Specific Considerations
Preventive Cardioprotection Strategy
For Duchenne/Becker muscular dystrophy specifically: Initiate ACE inhibitors no later than age 10 years, even before overt cardiomyopathy develops 4. Add an MRA when cardiac MRI shows fibrosis (late gadolinium enhancement), and add a beta-blocker for symptomatic tachycardia 4. This preventive approach delays cardiomyopathy progression.
Corticosteroids started early for skeletal/respiratory muscles also appear to delay cardiomyopathy 4.
When LVEF Falls Below 50%
Once left ventricular ejection fraction drops <50%, immediately implement full quadruple GDMT with the fastest feasible uptitration 4. Recent registry data show that SGLT2 inhibitors are safe and associated with modest LVEF improvement (41% to 44%, p=0.005) and reduced fatigue in muscular dystrophy patients 5.
Device Therapy
ICD placement follows standard NICM (non-ischemic cardiomyopathy) indications for both primary and secondary prevention when meaningful survival >1 year is expected 1.
Special considerations for specific dystrophies:
- Emery-Dreifuss and limb-girdle type 1B (Lamin A/C mutations): ICD is reasonable with progressive cardiac involvement, as life-threatening ventricular arrhythmias occur in ~52% of patients, including 40% with LVEF ≥45% 1
- Myotonic dystrophy type 1: When permanent pacemaker is indicated, consider ICD instead to minimize sudden cardiac arrest risk from ventricular tachycardia 1
Monitoring Requirements
Perform ECG and echocardiography at diagnosis and annually thereafter 4. Cardiac MRI with late gadolinium enhancement is superior for detecting early fibrosis before overt dysfunction 4, 6. Monitor BNP or NT-proBNP as biomarkers 4.
Follow-up for cardiac involvement is reasonable even in asymptomatic patients with muscular dystrophy 1.
Critical Pitfalls to Avoid
Undertreatment is Common
Real-world data from the HOPE-MD registry show only 16% of young adults with dystrophin-related cardiomyopathy receive full quadruple GDMT, with only 25% at ≥50% target dose 7. The greatest underutilization occurs with MRAs (51% prescribed) and SGLT2 inhibitors (22% prescribed) 7. Contraindications account for only a small proportion of undertreatment 7.
Delayed Recognition of Heart Failure
Clinical recognition of heart failure is often delayed in muscular dystrophy patients because:
- Loss of ambulation during early adolescence masks cardiovascular symptoms 6
- Relative physical inactivity keeps cardiomyopathy clinically silent 8
- Long subclinical phase of ventricular dysfunction 6
Do not wait for symptoms—initiate preventive therapy early based on imaging and biomarkers.
Respiratory Considerations
Advanced respiratory muscle weakness increases risks associated with ICD placement in advanced Duchenne muscular dystrophy 9. Hypoxemia (saturations <95%) requires urgent management with non-invasive ventilation, not oxygen alone, as oxygen without ventilation can worsen hypercapnia 10.
Advanced Heart Failure Options
Mechanical Circulatory Support
Left ventricular assist devices (LVADs) may be considered in carefully selected patients as bridge to transplantation or destination therapy 9. However, perioperative risk is higher due to skeletal muscle weakness, restrictive lung disease, and atypical thoracic anatomy from kyphoscoliosis 9. Post-LVAD survival is superior in patients with larger LV cavities (>46-50 mm) 11.
Cardiac Transplantation
Transplantation may be considered in carefully selected patients with end-stage heart failure despite optimal therapies 9. Successful transplantation has been reported for Becker, limb-girdle, Emery-Dreifuss, and other dystrophies where cardiomyopathy is disproportionately severe relative to skeletal/respiratory impairment 9.
The 2018 United Network for Organ Sharing policy includes separate listing criteria specific to patients with cardiomyopathy (including muscular dystrophy), significantly increasing transplantation rates and reducing waitlist times 11.
Palliative Care
Home parenteral inotropic therapy may be considered for symptom control in stage D heart failure when patients are not candidates for mechanical support or transplantation 9.